Interferons and the Immunogenic Effects of Cancer Therapy

Trends in Immunology

Volumn 36, Issue 11, 2015, Pages 725-737

  Minn, Andy J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSOME; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 9; CYTOCHROME C; INTERFERON;

ADAPTIVE IMMUNITY; APOPTOSIS; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL DEATH; CELL MEMBRANE PERMEABILITY; GENOTOXICITY; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION; NECROPTOSIS; NONHUMAN; PROTEIN FUNCTION; RADIATION RESPONSE; RADIOSENSITIVITY; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; IMMUNOLOGY; NEOPLASMS; PATHOLOGY;

ANIMALS; HUMANS; INTERFERONS; NEOPLASMS;

EID: 84946729972     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.09.007     Document Type: Review

References (91)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists Collaborative Group (EBCTCG).
2. Clarke M., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366:2087-2106.
3. Yom S.S. Radiation treatment of head and neck cancer. Surg. Oncol. Clin. N. Am. 2015, 24:423-436.
4. Rusthoven C.G., et al. Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data. Ann. Transl. Med. 2015, 3:149.
5. Chapman P.B., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364:2507-2516.
6. Helleday T., et al. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8:193-204.
7. Farmer H., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
8. Kroemer G., et al. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 2013, 31:51-72.
9. Coffelt S.B., de Visser K.E. Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends Immunol. 2015, 36:198-216.
10. Siva S., et al. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 2015, 356:82-90.
11. Postow M.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 2012, 366:925-931.
12. Loi S., et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 2013, 31:860-867.
13. Denkert C., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 2010, 28:105-113.
14. + T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014, 26:623-637.
15. + T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
16. Apetoh L., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
17. Deng L., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 2014, 124:687-695.
18. Verbrugge I., et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 2012, 72:3163-3174.
19. Demaria S., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 2005, 11:728-734.
20. Dewan M.Z., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 2009, 15:5379-5388.
21. Twyman-Saint Victor C.T-S., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520:373-377.
22. Green D.R., et al. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 2009, 9:353-363.
23. Pasparakis M., Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015, 517:311-320.
24. Nehs M.A., et al. Necroptosis is a novel mechanism of radiation-induced cell death in anaplastic thyroid and adrenocortical cancers. Surgery 2011, 150:1032-1039.
25. Dannappel M., et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 2014, 513:90-94.
26. Rongvaux A., et al. Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. Cell 2014, 159:1563-1577.
27. White M.J., et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell 2014, 159:1549-1562.
28. Weichselbaum R.R., et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18490-18495.
29. Ciampricotti M., et al. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat. Med. 2012, 18:344-346. author reply 346.
30. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
31. Cheon H., et al. Interferons and their stimulated genes in the tumor microenvironment. Semin. Oncol. 2014, 41:156-173.
32. Perou C.M., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
33. Wolf D.M., et al. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS ONE 2014, 9:e88309.
34. Harlin H., et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009, 69:3077-3085.
35. Galon J., et al. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013, 39:11-26.
36. Ulloa-Montoya F., et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J. Clin. Oncol. 2013, 31:2388-2395.
37. Gajewski T.F., et al. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 2011, 23:286-292.
38. Wilson E.B., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207.
39. Teijaro J.R., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211.
40. Finak G., et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 2008, 14:518-527.
41. Farmer P., et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 2009, 15:68-74.
42. Burnette B.C., et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 2011, 71:2488-2496.
43. Deng L., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014, 41:843-852.
44. Liang H., et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J. Immunol. 2013, 190:5874-5881.
45. Sistigu A., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 2014, 20:1301-1309.
46. Härtlova A., et al. DNA damage primes the type i interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity 2015, 42:332-343.
47. McAlpine J.N., et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod. Pathol. 2012, 25:740-750.
48. Jazaeri A.A., et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J. Natl. Cancer Inst. 2002, 94:990-1000.
49. Taniguchi K., et al. Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:3405-3409.
50. Lollini P.L., et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the γ-interferon gene. Int. J. Cancer 1993, 55:320-329.
51. Gobin S., van den Elsen P.J. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum. Immunol. 2000, 61:1102-1107.
52. Chen L.J., et al. Inhibition of HLA-G expression via RNAi abolishes resistance of extravillous trophoblast cell line TEV-1 to NK Lysis. Placenta 2010, 31:519-527.
53. Morel S., et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000, 12:107-117.
54. Porter G.A., et al. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann. Surg. Oncol. 2001, 8:116-122.
55. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
56. Lee S-J., et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 2006, 580:755-762.
57. Yang X., et al. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 2014, 25:37-48.
58. Taube J.M., et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 2012, 4:127ra37.
59. Tumeh P.C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515:568-571.
60. Akbay E.A., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013, 3:1355-1363.
61. Atefi M., et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin. Cancer Res. 2014, 20:3446-3457.
62. Herbst R.S., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
63. Powles T., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.
64. + T Cells. Sci. Transl. Med. 2013, 5:200ra116.
65. Markel G., et al. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology 2009, 126:186-200.
66. Holmgaard R.B., et al. Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 2013, 210:1389-1402.
67. Huang Y-H., et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2015, 517:386-390.
68. Crouse J., et al. Regulation of antiviral T cell responses by type I interferons. Nat. Rev. Immunol. 2015, 15:231-242.
69. Khodarev N.N., et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res. 2007, 67:9214-9220.
70. Park J.M., et al. Modification of PCNA by ISG15 plays a crucial role in termination of error-prone translesion DNA synthesis. Mol. Cell 2014, 54:626-638.
71. Klemm F., Joyce J.A. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015, 25:198-213.
72. Boelens M.C., et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 2014, 159:499-513.
73. Woo S-R., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41:830-842.
74. Stetson D.B., et al. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008, 134:587-598.
75. Bernard J.J., et al. Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat. Med. 2012, 18:1286-1290.
76. Rudin C.M., Thompson C.B. Transcriptional activation of short interspersed elements by DNA-damaging agents. Genes Chromosomes Cancer 2001, 30:64-71.
77. Liddicoat B.J., et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science 2015, 349:1115-1120.
78. Chiappinelli K.B., et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 2015, 162:974-986.
79. Roulois D., et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 2015, 162:961-973.
80. Cheon H., Stark G.R. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9373-9378.
81. Cheon H., et al. IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 2013, 32:2751-2763.
82. Sandler N.G., et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 2014, 511:601-605.
83. Arimoto K-I., et al. Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:7500-7505.
84. Zhu J., et al. Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor. Immunity 2014, 40:936-948.
85. Ibsen M.S., et al. Structural and functional analysis reveals that human OASL binds dsRNA to enhance RIG-I signaling. Nucleic Acids Res. 2015, 43:5236-5248.
86. Malakhova O.A., et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J. 2006, 25:2358-2367.
87. Porritt R.A., Hertzog P.J. Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends Immunol. 2015, 36:150-160.
88. Rice G.I., et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat. Genet. 2012, 44:1243-1248.
89. Bald T., et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014, 4:674-687.
90. Fu J., et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med. 2015, 7:283ra52.
91. McNab F., et al. Type I interferons in infectious disease. Nat. Rev. Immunol. 2015, 15:87-103.